What is Inclisiran?

Inclisiran is an innovative small interfering RNA (siRNA) therapeutic designed to lower low‑density lipoprotein cholesterol (LDL‑C) by inhibiting the hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9). By reducing PCSK9 levels, inclisiran increases the number of LDL receptors on hepatocytes, thereby enhancing the clearance of LDL‑C from the bloodstream.

Reference: U.S. Food and Drug Administration (FDA) Leqvio Prescribing Information; ClinicalTrials.gov ORION studies (e.g., NCT03397194)

---

What are the other popular names for Inclisiran?

Inclisiran is primarily marketed under the brand name Leqvio®. In clinical discussions and literature, it is also referred to by its generic name, inclisiran.

Reference: U.S. FDA; MedlinePlus; ClinicalTrials.gov

---

What is the drug classification of Inclisiran?

Inclisiran is classified as an RNA interference (RNAi) therapeutic and is grouped as a PCSK9 inhibitor. Unlike traditional monoclonal antibody PCSK9 inhibitors, inclisiran uses siRNA technology to reduce PCSK9 synthesis in the liver.

Reference: World Health Organization (WHO) guidelines on lipid management; U.S. FDA

---

What is the mode of action of Inclisiran?

Inclisiran works by entering hepatocytes and incorporating into the RNA-induced silencing complex (RISC). Once loaded into RISC, it specifically binds to the messenger RNA (mRNA) that encodes PCSK9, leading to its degradation. As a result, less PCSK9 protein is produced, which increases the recycling and expression of LDL receptors on liver cells. This enhanced receptor activity facilitates greater clearance of LDL‑C from the circulation.

Reference: PubMed (e.g., Ray et al., 2017 on RNAi mechanisms); U.S. FDA

---

What are the primary uses of Inclisiran?

Inclisiran is used as an adjunct to diet and maximally tolerated statin therapy for the treatment of:

• Heterozygous Familial Hypercholesterolemia (HeFH)
• Atherosclerotic Cardiovascular Disease (ASCVD)
  It is indicated in adults who require additional LDL‑C lowering.

Reference: U.S. FDA; ClinicalTrials.gov (ORION-9, ORION-10, ORION-11 studies)

---

What is the recommended dosage and administration for Inclisiran?

• Dosage:
  • The recommended regimen is two subcutaneous injections in the first year—one at Day 0 and a second at Day 90—followed by maintenance injections every six months.
• Administration:
  • Inclisiran is administered by subcutaneous injection. Consistency in the injection schedule is key to maintaining its LDL‑C–lowering effect.

Reference: U.S. FDA Leqvio Prescribing Information; ClinicalTrials.gov (e.g., ORION‑10 study NCT03399370)

---

What prescribing information is important for Inclisiran?

• Indications:
  • Inclisiran is indicated for patients with HeFH or established ASCVD who need additional LDL‑C reduction despite being on maximally tolerated statin therapy.
• Contraindications:
  • Known hypersensitivity to inclisiran or any of its components.
• Monitoring:
  • Regular monitoring of lipid panels, liver function, and injection site reactions is recommended.
• Special Considerations:
  • Patient education on proper injection technique and adherence to the dosing schedule is essential.

Reference: U.S. FDA; National Institutes of Health (NIH) guidelines on lipid management

---

What safety information, side effects, warnings, and cautions are associated with Inclisiran?

• Common Side Effects:
  • Injection site reactions (e.g., redness, pain, or swelling)
  • Mild nasopharyngitis or flu-like symptoms
• Less Common/Serious Side Effects:
  • Rare allergic reactions
  • Transient elevations in liver enzymes (monitoring recommended)
• Warnings & Cautions:
  • Injection Site Reactions: Patients should be advised about the possibility of local reactions.
  • Liver Function: Although systemic exposure is low, periodic liver function tests are advised in patients with pre-existing liver conditions.
  • Pregnancy and Lactation: Inclisiran is not recommended during pregnancy or breastfeeding due to insufficient data on safety.
• Additional Cautions:
  • Because inclisiran is administered infrequently (every six months after initial dosing), adherence to follow-up is essential.

Reference: U.S. FDA Leqvio Prescribing Information; PubMed

---

What drug interactions should be considered with Inclisiran?

• Concomitant Lipid-Lowering Therapies:
  • Inclisiran is designed to be used in combination with maximally tolerated statin therapy. There are no major drug interactions that contraindicate its use with other lipid‑lowering agents; rather, its effects are complementary.
• Immunomodulatory Agents:
  • Although inclisiran is an siRNA therapeutic with a targeted mechanism, always inform the healthcare provider of all concurrent medications to ensure there are no unforeseen interactions.
• General Consideration:
  • Due to its specific mechanism of action (RNA interference), inclisiran has a low potential for typical drug–drug interactions seen with small molecule drugs.

Reference: U.S. FDA; ClinicalTrials.gov (ORION studies); PubMed

---

What FAQs might patients have about Inclisiran?

Q: How does Inclisiran differ from monoclonal antibody PCSK9 inhibitors?
A: Unlike monoclonal antibodies, which bind circulating PCSK9, inclisiran uses siRNA technology to reduce PCSK9 production at the genetic level, offering a prolonged effect with just two initial doses and maintenance dosing every six months.

Q: How effective is Inclisiran in lowering LDL‑C?
A: Clinical trials (e.g., ORION‑10 and ORION‑11) have shown that inclisiran can reduce LDL‑C levels by approximately 50% when used in conjunction with statin therapy.

Q: What are the common side effects of Inclisiran?
A: The most common side effects include injection site reactions, such as mild redness or swelling, and occasionally mild flu-like symptoms.

Q: Is Inclisiran safe to use during pregnancy?
A: Inclisiran is not recommended during pregnancy or breastfeeding due to limited safety data in these populations.

Q: How is Inclisiran administered?
A: It is given as a subcutaneous injection—an initial dose, a second dose at 90 days, and then maintenance injections every six months.

Reference: U.S. FDA; ClinicalTrials.gov (ORION‑10, ORION‑11); New England Journal of Medicine (NEJM)

---

Where can I find additional clinical evidence and detailed information about Inclisiran?

For further details on clinical studies, dosing guidelines, and safety monitoring, refer to:

• U.S. Food and Drug Administration (FDA) Website: FDA.gov
• ClinicalTrials.gov: (e.g., ORION‑9, ORION‑10, ORION‑11 trials)
• New England Journal of Medicine (NEJM): Publications on inclisiran efficacy and safety
• World Health Organization (WHO) and American Heart Association (AHA): Guidelines on lipid management

Reference: U.S. FDA; ClinicalTrials.gov; NEJM; WHO; AHA

---

Final Thoughts

Inclisiran (Leqvio®) is a groundbreaking siRNA therapeutic that offers significant LDL‑C reduction in patients with familial hypercholesterolemia or atherosclerotic cardiovascular disease when added to standard lipid‑lowering therapy. With its unique dosing regimen—an initial two-dose series followed by biannual maintenance injections—it provides a convenient treatment option that can enhance patient adherence. Although inclisiran is generally well tolerated, proper patient selection, monitoring of liver function, and adherence to injection schedules are critical to maximize its benefits while minimizing potential risks. Always consult your healthcare provider to determine if inclisiran is appropriate for your treatment plan.

Disclaimer: This information is provided for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.